A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
PHASE3CompletedINTERVENTIONAL
Enrollment
386
Participants
Timeline
Start Date
January 31, 2014
Primary Completion Date
August 31, 2017
Study Completion Date
August 31, 2017
Conditions
Liver Cancer
Interventions
DRUG
ARQ197
DRUG
Placebo
Trial Locations (1)
Unknown
Cancer Centers in Japan, Tokyo
All Listed Sponsors
lead
Kyowa Kirin Co., Ltd.
INDUSTRY
NCT02029157 - A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter